# QUINTESSENTIAL-2: HCP commentary report > 10 HCP sources screened · 227 verified claims from 8 sources · 9 findings. Updated 2026-10-09. ## Report - Trial: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma - NCT ID: NCT06615479 - Registry: https://clinicaltrials.gov/study/NCT06615479 - Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company - Phase: Phase 3 - Status: Recruiting - Drugs: arlocabtagene autoleucel, cyclophosphamide, fludarabine, daratumumab, pomalidomide, dexamethasone, carfilzomib - Indications: Multiple myeloma - Version: v1.0.0, edition 1 - Accepted: 2026-10-09 - Last checked: 2026-10-09 - Release hash: 7cf6c378989c07c718bc8393e5ed30ab3274a113041e5f3c9e3b9fa60dba4d5b ## Counts - HCP commentary sources screened: 10 - Sources cited by verified claims: 8 - Verified claims: 227 - Findings: 9 - People found in screened sources: 6 - People identity-verified: 4 - Voices cited: 13 Counts describe the retained sources. They do not estimate how many HCPs hold a view. ## Abstract QUINTESSENTIAL-2 anchors clinicians' discussion of where arlocabtagene autoleucel (arlo-cel), a GPRC5D-directed CAR-T, could fit for adults with relapsed or refractory, lenalidomide-exposed multiple myeloma. Topics include the comparative benefit that would matter against daratumumab, pomalidomide and dexamethasone or carfilzomib and dexamethasone, GPRC5D-related and neurologic toxicity, sequencing around BCMA-directed therapy, earlier CAR-T use and MRD, referral and access, bridging, and options for patients who defer or cannot receive CAR-T. Coverage is limited to the reviewed commentary sources. ## Open Medical Affairs question What comparative benefit would distinguish target diversification from a clinically meaningful improvement over the trial's standard-care options? ## Findings (titles) - F1. An attractive non-BCMA option, with superiority still an open question - F2. Less persistent GPRC5D toxicity does not resolve the non-ICANS neurologic signal - F3. Post-BCMA placement is attractive, but antigen switching is not an automatic rule - F4. Earlier CAR-T is framed as a remission opportunity, not a guaranteed cure - F5. Referral and access remain limiting even when enthusiasm and center capacity improve - F6. Holding and bridging therapy have different purposes and different constraints - F7. CAR-T deferral prompts risk-adapted alternatives, with substantial supportive-care qualifications - F8. Off-the-shelf alternatives depend on eligibility, sequencing and treatment burden - F9. MRD is discussed as an earlier evidence signal and a treatment-stop question—not a stopping rule ## Sample findings ## Trial aspects | Aspect | Coverage | Claims | Sources | | --- | --- | ---: | ---: | | Primary endpoint: Progression Free Survival (PFS) | discussed | 10 | 5 | | Primary endpoint: Minimal residual disease (MRD)-negativity in complete response (CR) | discussed | 8 | 2 | | Secondary endpoints | discussed | 7 | 6 | | Population and setting | discussed | 15 | 6 | | The comparison | discussed | 8 | 4 | | Safety and tolerability | discussed | 18 | 6 | | Design and conduct | discussed | 7 | 5 | | Antigen selection and resistance-informed sequencing | discussed | 38 | 4 | | Earlier CAR-T, durable remission and treatment-free goals | discussed | 34 | 3 | | Referral, travel, center access and participation constraints | discussed | 25 | 7 | | Pre-apheresis holding versus pre-infusion bridging | discussed | 15 | 2 | | CAR-T deferral and CELMoD-based alternative regimens | discussed | 30 | 2 | | Off-the-shelf alternatives, ineligibility and selective withholding | discussed | 32 | 2 | ## Cited sources by channel - Podcasts: 1 - X threads: 1 - YouTube: 6 ## Scope and limits This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice. - Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing. - 10 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up. - Out of scope in retained sources: 21 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition. - Further source limits: the search also described the trial without its name, to find discussion that does not name it; sources found that way were screened by their titles before any was read; some of those sources were set aside as about other trials. - The reviewed material is not a representative sample of HCP opinion. Discussion without the indexed trial name or aliases, including unnamed references or transcription variants, may be absent; the report therefore cannot establish prevalence or consensus. - No exact-trial publication or standalone protocol was available in the supplied material, and regulatory context for BMS-986393 was incomplete. This limits independent interpretation of the trial-specific questions raised by speakers. - Earlier-study efficacy and safety figures are attributed speaker accounts with differing populations, doses, follow-up or unspecified comparisons. They are not QUINTESSENTIAL-2 results and should not be combined as one estimate. - Anonymous panel passages cannot be assigned to nearby named speakers. Moderator summaries and reported prior responses do not establish individual ownership of votes or preferences. - Several timing statements are forecasts or publication-relative expectations. The report does not reconcile them into a verified enrollment or readout chronology. ## Offer - Size: Focused (8 commentary sources cited) - Current edition: $750. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge - 3 months of weekly updates: $1,300 - 6 months of weekly updates: $1,900 - 12 months of weekly updates: $2,600 - Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (4 now), at most $750; people verified later in the term at no charge - Pricing: https://www.erudio.com/pricing - Buy now (card, through Stripe): https://www.erudio.com/reports/quintessential-2-nct06615479 - Agents: POST https://www.erudio.com/api/orders with {"report": "quintessential-2-nct06615479", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": ""}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again - Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=quintessential-2-06615479 ## Cite Erudio Health. QUINTESSENTIAL-2 (NCT06615479): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-09. https://www.erudio.com/reports/quintessential-2-nct06615479 ## Machine access - JSON: https://www.erudio.com/reports/quintessential-2-nct06615479.json - MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "quintessential-2-06615479"}`